Reaction
Focal Nodular Hyperplasia reporting signals
As of the last recalculation, Focal Nodular Hyperplasia appears in 520 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 110.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 25 | 110.0 | 110.3 |
| Canakinumab | 16 | 61.0 | 61.1 |
| Oxaliplatin | 81 | 51.6 | 51.6 |
| Busulfan | 19 | 50.1 | 50.2 |
| Ado-Trastuzumab Emtansine | 9 | 43.5 | 43.5 |
| Indomethacin | 14 | 43.4 | 43.5 |
| Anakinra | 16 | 39.8 | 39.8 |
| Alemtuzumab | 18 | 38.6 | 38.6 |
| Fluorouracil Cream, 0.5% | 58 | 34.1 | 34.2 |
| Drospirenone And Ethinyl Estradiol | 35 | 33.9 | 33.9 |
| Fluorouracil | 58 | 33.7 | 33.7 |
| Thalidomide | 17 | 19.1 | 19.1 |
| Etonogestrel And Ethinyl Estradiol | 10 | 18.4 | 18.4 |
| Etoposide | 31 | 17.9 | 17.9 |
| Levonorgestrel | 50 | 10.9 | 10.9 |
| Somatropin | 14 | 7.8 | 7.8 |